The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders

Carlos Roncero, F. Javier Álvarez

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Lisdexamfetamine dimesylate (LDX) is a long-acting oral prodrug stimulant. It is inactive until enzymatically hydrolyzed in the blood to active d-amphetamine. The pharmacological action of this compound involves blocking norepinephrine (NE) and dopamine reuptake into presynaptic neurons and promoting the release of NE and dopamine into the extraneuronal space. LDX has been approved for treating ADHD, which is the most common psychiatric disorder in children and adolescents. Also, LDX has been proposed for other psychiatric conditions related with dopaminergic and NE CNS. LDX is the first long-acting oral prodrug indicated for the treatment of ADHD in children (6-12 years), adolescents (13-17 years) and in adults in the USA and Canada, whereas, in Europe, LDX is licensed in several countries for the treatment of children and adolescents with ADHD who have had a clinically inadequate response to methylphenidate. This article covers the most important pharmacological aspects of LDX as well as data on the efficacy, tolerability and safety of this long-acting amphetamine prodrug collected from clinical studies recently published in the literature. © 2014 Informa UK, Ltd.
Original languageEnglish
Pages (from-to)849-865
JournalExpert Review of Neurotherapeutics
Volume14
Issue number8
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • ADHD
  • efficacy
  • lisdexamfetamine dimesylate
  • prodrug
  • safety
  • tolerability

Fingerprint Dive into the research topics of 'The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders'. Together they form a unique fingerprint.

Cite this